If you find this podcast useful please give it a rating and review on iTunes by clicking here
Do you want to get instant company alerts to the front screen of your smartphone? Download the Vox Markets app here: www.VoxMarkets.co.uk/app
On today's Vox Markets Podcast: Versarian, Open Orphan (was Venn Life Sciences) and Russ Mould on 3 Stocks
Neill Ricketts, Chief Executive Officer of Versarien (VRS) discusses their first graphene order from a US based company and their New Head of US Operations.
Versarien plc (VRS), is an advanced engineering materials group. Leveraging proprietary technology, the Group creates innovative engineering solutions for its clients in a diverse range of industries. Versarien has five subsidiaries operating under two divisions: Graphene and Plastics Thermal and Hardware Products.
Cathal Friel, Chief Executive Officer of Open Orphan (ORPH) previously Venn Life Sciences, explain their 4 legged strategy to achieve growth in the pharmaceutical services industry.
Open Orphan plc is a European-focussed, rare and orphan drug consulting services platform. The Company consists of four elements: a European clinical research organisation and consultancy; an orphan drug services business; a Virtual Rep and Data Access Platform consisting of physicians and key opinion leaders; and a Health Data Platform to partner with Patient Advocacy Groups. The Company is targeting rapid growth in one of the fastest growing sectors in the global pharmaceutical industry targeting under-supplied treatment for life threatening or very serious diseases and rare disorders.
(Interview starts at 14 minutes 34 seconds)
Russ Mould, Investment Director at stockbroker AJ Bell talks about:
Pressure Technologies (PRES)
Morses Club (MCL)
Marston’s (MARS)
(Interview starts at 28 minutes 10 seconds)